Table 1.

Characteristics of the included studies.

First Author (Year)	Study Period	Sample size (T/C n)	TNM Stage	Drug Delivery	TCM Duration	TCM Intervention	Paclitaxel Regimen	TRR (T/C n)
Chen (2009)	2005–2007	34/33	IIIb: 23/24; IV: 11/9	Injection	6w	Huachansu injection	TPF: PTX+PDD+5-FU	15/12
Ge et al. (2014)	NR	20/20	Advanced stage	Orally	8w	Jianpixiaozheng decoction	TS: PTX+S-1	10/9
Huang et al. (2018)	2015–2016	50/50	Advanced stage	Injection	18w	Kanglaite injection + Jianpiyiqi decoction	TP: PTX+PDD	35/20
Lai et al. (2018)	2015–2018	30/30	IV	Orally	6w	Shenlingbaizhu decoction	TCF: PTX+CF+5-FU	NR
Li N. J., et al (2016)	2013–2014	25/25	Advanced stage	Orally	4w	Rg3+Shenyi capsule	TCF: PTX+CF+5-FU	17/11
Li et al. (2010)	2007–2009	42/40	Advanced stage	Orally	22d	Liujunzi decoction	TCF: PTX+CF+5-FU	25/23
Li et al. (2016a)	2012–2015	33/32	IV	Injection	8w	Fufangkushen injection + Yiqiyangwei decoction	PTX	27/18
Li et al. (2016b)	2014–2015	50/50	Advanced stage	Orally	8w	Shenlingbaizhu decoction	TS: PTX+S-1	27/22
Liao (2018)	2015–2016	31/31	Advanced stage	Injection	4w	Kang'ai injection	PTX+CF	27/19
Liu and Zhang (2009)	2006–2008	30/30	IIIb: 17/14; IV: 13/16	Injection	20d	Aidi injection	TPF: PTX+PDD+5-FU	16/16
Meng (2019)	2015–2016	50/50	III: 34/36; IV: 16/14	Injection	12w	Fufangkushen injection	PTX	35/15
Tan et al. (2013)	2007–2011	40/46	IV	Orally	6w	Fufangbanmao capsule	PTX+5-FU+LV	19/12
Xue and Mao (2017)	2013–2015	45/45	Advanced stage	Orally	8w	Rg3	TCF: PTX+CF+5-FU	35/28
You and Huang (2009)	2007–2008	22/24	III:6/5; IV:16/19	Orally	24w	Fuzhenghewei liquid medicament	TP: PTX+PDD/TCF: PTX+CF+5-FU	8/8

T, treatment group; C, control group; TNM, cancer staging system; NR, not reported; TCM, traditional Chinese medicine, TRR, tumor response rate; w, week; d, day; PTX, paclitaxel; PDD, cisplatin; 5-FU, 5-fluorouracil; CF, calcium folinate; LV, leucovorin.